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ABSTRACT 
 
The major histocompatibility complex (MHC) is an allele-rich and exceptionally gene 
dense region on human chromosome 6. Over 40% of the genes in this region have 
immune-related functions, including genes encoding MHCI and MHCII molecules. 
These molecules, which are found in nearly all vertebrates, present antigenic peptides to 
CD4 and CD8 T cells. Alleles of MHCI and MHCII are believed to be strong risk factors 
in autoimmune disorders, such as rheumatoid arthritis (RA), as well as in infectious 
diseases. However, the differentiation between haplotype and allele associations in the 
MHC is not straightforward. Strong linkage disequilibrium exists between gene 
segments throughout the region and impedes identification of disease associated 
variants. These gene segments can be isolated and studied individually in congenic mice 
and rats. We produced for this thesis an extensive number of intra-MHC congenic rats 
to study the association between MHC genes and experimental arthritis, T cell selection 
and MHC regulation. Study I describes a genome-wide approach in heterogenous stock 
rats to identify quantitative trait loci (QTLs) associated with variations in MHC levels 
and CD4 and CD8 T cell numbers. A total of 10 QTLs were identified, of which 3 
mapped to the MHC. We showed by congenic mapping that two minimal haplotypes of 
~0.2 Mb explained the associations to the MHC. We further identified two allelic 
variants of the gene Tap2 that contributed to the variation in T cell numbers. Study II 
describes the effect of these minimal haplotypes on arthritis development and positions 
the MHCII region for the first time in an adjuvant model. We show that genes in the 
MHCII regulate onset, progression and severity of arthritis but not chronicity. 
Comparative analyses of different congenic MHCII haplotypes showed an inverse 
correlation between arthritis severity and proportion of recent thymic emigrants. Study 
III shows an MHCII associated T cell response to the cartilage protein collagen type XI 
in chronic pristane-induced arthritis (PIA) and the corresponding antibody response to 
the same antigen in human RA. Study IV  describes the adoptive transfer of PIA in DA 
rats and outlines the conditions necessary for the model.   
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GENETIC MAPPING 
 
 
Introduction to genetic mapping 
 
There are several strategies to map genes in animals and most, if not all, of these are 
based on the existence of genetic markers. These markers, which are relatively common 
(microsatellites) or very common (single nucleotide polymorphisms), are used to 
position quantitative trait loci (QTLs) within the genome, either by linkage or 
association. A classical method to position (or map) QTLs is to study genetic 
segregation by linkage in a cross between two inbred strains. The method is simple but 
rarely provides information on gene level. However, it does provide a good starting 
point for a congenic strain, in which a segment from one strain is inserted (or isolated) 
within the genome of another strain. In contrast to a cross, a congenic strain is 
genetically stable and therefore suitable for functional studies. 
The poor resolution that is obtained in a two-strain segregation study is the major 
disadvantage of the method. A heterogenous stock is derived from a larger number of 
founder strains and the allelic diversity is therefore greater than in a conventional cross. 
By increasing the allelic diversity, the number of phenotypes that can be captured 
increases and more QTLs can be identified for each phenotype. However, a 
heterogenous stock does not necessarily lead to increased resolution, as the resolution is 
dependent on the recombination frequency. More recently, other types of crosses have 
been developed or are currently under development, such as the collaborative cross1 
and outbred crosses2.   
Regardless of model, mapping genes in animals to explain phenotypes in humans 
depend on (1) the quality of the phenotype (how relevant the phenotype is for the 
human trait), and (2) genetic heterogeneity. The quality of the phenotype, for example 
arthritis, is only valuable if it shares mechanisms relevant to the human trait 
(rheumatoid arthritis in this case). The second point (genetic heterogeneity) relates to 
the disadvantage with a conventional cross. Traits associated with rare alleles in 
humans might be associated with rare alleles also in other species. Hence, the chances of 
identifying a gene depend on its allele frequency in a population. Fortunately, different 
genetic variants may produce similar effects and, hence, a gene may be identified in an 
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animal model even if the causative variant is not the same in humans. Moreover, a gene 
may be mapped to a pathway that is of relevance in humans even if the gene itself is not.  
Below, I describe strategies for genetic mapping that are of relevance for this 
thesis, in particular the generation of congenic and recombinant strains. First, however, 
I discuss the evolution of genetic markers and the importance of recombinations, which 
is the basis of virtually all genetic mapping.   
 
 
Evolution of genetic markers 
 
The advent of modern agriculture in the 1930s demanded new strategies to control 
breeding (Figure 1). However, in the beginning of the century, suitable markers were 
limited to morphological and biochemical phenotypes and it was not until the 
development of restriction fragment length polymorphisms (RFLPs) in 1974, 
researchers for the first time could use genetic markers to detect QTLs3. Although 
diallelic, RFLPs were believed to exist throughout the genome, and therefore be suitable 
for genetic mapping. Indeed, these markers were used to perform the first genome-wide 
scan, which was conducted on tomatoes by Paterson in 19884. However, since they are 
diallelic and therefore non-informative (homozygous) in many loci, RFLPs were less 
suitable for large genetic studies in animal species.  
It has been known since the 1960s that a large proportion of the genome consists 
of repetitive sequences. These sequences, which are mainly dinucleotide repeats, are 
found almost exclusively in non-coding regions, and at least some of these sequences 
seem to have regulatory properties5. Three groups showed independently in 1989 that 
these repetitive sequences, which were named microsatellites or short tandem repeats 
(STRs), if consisting of less than 6 base pairs, were suitable for genetic studies6-8. 
Microsatellites were more frequent than RFLPs and easier to use than these. Most 
importantly, these new markers were polymorphic, also in animals, and by definition 
codominant (i.e. heterozygous and homozygous alleles are informative). Hence, 
microsatellites could be used to generate dense genetic maps for a large number of 
species. However, their relatively high mutation rate makes them evolutionary instable. 
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Although of minor importance in a conventional cross, this "drift" in genotypes makes 
them incompatible for tracking ancestry in population studies.   
Today, single nucleotide polymorphisms (SNPs) have largely replaced 
microsatellites. The accomplishment of the human genome sequence in 2003 showed a 
remarkable genetic variation, of which most were polymorphisms in single nucleotides, 
and by using SNPs, genetic associations could be obtained with a much higher 
resolutions than with microsatellites.  
 
 
 Recombinations and mapping resolution  
 
Recombinations, or chromosomal crossovers, involve the exchange of genetic material 
between different chromosomes or, to a less extent, between different regions on the 
same chromosome. Recombinations and mutations are together responsible for 
creating the patterns of genetic diversity and variation. Crossovers do not occur 
uniformly on the chromosomes but rather within narrow intervals of 1-2.5 kb9-11. These 
intervals, which are referred to as recombination hotspots, are scattered throughout the 
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genome. However, they are more common near the telomeres, and less common on the 
X-chromosome than on the autosomes, at least in rodents12. Moreover, recombination 
frequencies differ between species, being about two-fold greater in humans (~1.2 
cM/Mb) than in rodents (~0.55 cM/mb). They are also more common on smaller 
chromosomes than on larger12. Recombinations are also more frequent in oocytes than 
in sperms and, hence, the recombination rate is higher in females than in males. An 
exception seems to be recombinations near the telomeric regions, which are more 
common in males13.  
Studies in humans have shown that the average distance between hotspots is 50 
kb and that roughly 80% of the genome is unaffected by recombinations14. No 
consensus sequence has been found so far to explain the existence of recombination 
hotspots. However, certain repetitive sequences, in particular those with high GC-
content and multiple CpG islands, are positively correlating with the presence of 
recombination hotspots15. That hotspots are sequence related is consistent with studies 
in mutated yeast cells16 and from studies in mice, which have shown that 
recombinations are haplotype dependent17,18. Interestingly, hotspots emerge and, 
mainly, disappear in a rate that is disproportionate to the change in nucleotide 
sequence, which suggests that epigenetic modifications may contribute to the variation 
in recombination frequency19. In addition, active hotspot alleles are rapidly replaced by 
inactive, suggesting that the recombination frequency is steadily decreasing in a 
population20. That hotspots are not conserved between humans and chimpanzees, 
which is our closest living evolutionary relative (humans and chimpanzees share 99% 
sequence similarity), is therefore not surprising19. However, while hotspots evolve 
rapidly, recombination rates are constrained over larger intervals (several Mb), even 
between species.  
Recombination data are available from pedigrees, linkage analysis and from 
genotyping of single-sperm cells21-23. Sperm typing has been the chief method to detect 
recombinations in humans as it can be used to screen thousands of haploid cells. 
However, today recombinations can be inferred indirectly by using high-density 
sequence polymorphism data. Although based on historical recombinations and 
estimations, these data are largely consistent with data from sperm typing.  
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Segregation and linkage analyses  
 
Linkage mapping (or family mapping) uses family data, or pedigrees, to identify genetic 
regions that are associated with a trait. This information can further be used to establish 
a congenic strain or an advanced intercross line24. The regions that are identified in a 
linkage study are large, often in the order of 10s of megabases or more25 and the 
information that can be obtained is therefore limited. Furthermore, QTLs that consist 
of multiple linked genes with alleles that have opposite effects on a trait will be difficult 
to detect with a linkage study. Hence, a linkage study will underestimate the true 
number of QTLs in a population.   
In order to obtain a linkage map, genotype information needs to be collected 
from a set of genetic markers. However, since the expected number of recombination 
events is low in a cross or in a small set of family members, a relatively small number of 
markers need to be typed. Moreover, markers do not need to be physically mapped to 
the genome to be used in a linkage study since only the linkage (and not the physical 
distance) between traits and markers is studied.  
A schematic illustration showing the principles of linkage mapping is shown in 
Figure 2. In this example, genetic loci are segregating in a cross between two 
homozygous strains (represented as blue and red chromosomes in Figure 2A). 
Naturally, chromosomal crossovers that take place in homozygous individuals will not 
be informative, and the first generation (F1) therefore consists of genetically identical 
animals only. Whether markers that are linked in the F1 individual will remain linked 
after meiosis depends on the distance between them (Figure 2B).  Markers that are far 
apart are less likely to be inherited together and markers that are inherited more often 
than expected are said to be in linkage disequilibrium (LD). If markers are positioned 
on different chromosomes, the recombination frequency between them is 50%. To 
express the linkage between markers and traits or between different markers, geneticists 
use LOD scores (logarithm of odds; Figure 2C). While a positive LOD score suggests a 
true linkage, the significant threshold is dependent on each particular experiment. 
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Congenic strains and recombinant lines 
 
Congenic fine-mapping of loci identified by linkage mapping is a proven strategy to 
positionally clone genes26,27. The resolving power of congenic mapping is determined by 
the gene density in a particular region of interest and the capacity to generate and 
screen a sufficiently large number of mice or rats. It is possible to theoretically estimate 
how many animals that are needed to reduce a region to a fragment of a particular 
size28. For example, to obtain a 0.15 cM fragment from a 4 cM region requires ~1300 
mice, whereas ~40.000 mice would be required to achieve the same results by typing a 
conventional intercross29. Thus, a congenic strategy is ideal to fine-map a locus, while a 
linkage study is necessary to identify suitable QTL candidates. However, promising 
QTLs with strong and significant linkage may also fractionate into multiple smaller 
effects or, worse, into no effect at all when genetic interactions are broken30.  
To generate a congenic strain by conventional breeding is time-consuming as it 
requires at least 10 backcross generations, corresponding to 2.5 - 3 years time, to obtain 
a 99.9% pure genetic background31. By marker-assisted breeding, the same purity can be 
achieved with half as many backcross generations32. However, this speed congenic 
method requires more genotyping and therefore more hands-on work. A congenic 
fragment that is isolated by speed congenic or conventional methodologies is on 
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average 20 cM32. A first step towards positional cloning is therefore to generate sub-
congenic or recombinant strains. This is accomplished by segregation analysis, using 
the same principles as outlined in Figure 2. However, since the congenic region is 
defined by its physical fragment no other markers than those specific for the fragment 
need to be typed.  
A positional cloning approach will rarely lead to a single-gene fragment. More 
often, genes have to be excluded by other means, such as sequencing and expression 
analysis. By comparing alleles from different haplotypes, candidate variants can be 
identified and non-polymorphic gens can be excluded. This strategy, which was used 
for Study I and Study II in this thesis, is particularly suitable when dissecting a highly 
polymorphic region that is constrained by strong LD.  
 
 
Heterogeneous stock 
 
Heterogeneous stock (HS) animals provide QTLs at a higher resolution than a 
conventional cross and the mapping is less laborious than with a congenic strain33. An 
HS is derived from eight inbred founder strains that have been semi-randomly bred for 
40-50 generations, which should maintain heterozygosity. Thus, in contrast to a 
conventional cross, in which the mapping resolution is dependent on new 
recombination events, the recombinations in an HS have accumulated over 
generations. It is therefore possible to map QTLs with high resolution within a 
relatively short time period.  
Haplotype blocks (i.e. the distance between recombinations) in an HS approaches 
2 cM (~3 Mb in mouse) and, hence, the resolution is 10-fold higher in an HS than in a 
conventional cross. Corresponding haplotype blocks in humans and outbred mice are 
~9-18 kb and 100 kb, respectively34. Although better resolving power, the fixed strain 
composition in an HS is a limitation. In a conventional cross, strains are selected 
specifically for their phenotype. For example, a cross aiming to detect QTLs for diabetes 
needs to contain both diabetes susceptible and resistant alleles. In an HS, however, the 
strain composition is fixed and whether the stock is suitable needs to be tested 
empirically. In mice, two separate but strain-wise similar stocks are available: the 
Boulder and the Northport stocks30,35,36. Thus, there is at least a theoretical possibility to 
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assess suitability in two different stocks. The only HS that has been developed in the rat 
was founded at the NIH in 1984, using the inbred strains ACI/N, BN/N, BUF/N, 
F344/N, M520/N, MR/N, WKY/N and WN/N37. We used the NIH-HS to detect QTLs 
associated with variations in T cell subsets and MHC expression in Study I. However, 
our first intention was to use this stock to map genes controlling pristane-induced 
arthritis (PIA), a model for rheumatoid arthritis. However, the NIH-HS turned out to 
lack critical arthritis promoting alleles38,39, and a pilot study on ~100 HS individuals 
confirmed that it was not suitable for this purpose (Rintisch, unpublished data). 
Ahlqvist et al. experienced similar problems when using the Northport stock to map 
arthritis susceptible genes in collagen-induced arthritis (CIA)40. Susceptibility to CIA is 
strictly dependent on H2-Aq and H2-Ar MHCII alleles. Since neither of these MHCII 
haplotypes were represented in the Northport stock, it was not surprising that the 
Northport stock would be resistant to CIA41. Ahlqvist et al. therefore introduced the 
arthritis permitting H2-Aq MHC haplotype from the BQ strain in the Northport stock, 
a strategy originally proposed by Mott and Flint42. Homozygous H2-Aq mice were 
selected to produce an F3 generation with fixed MHC alleles, which they used for 
arthritis experiments. However, by introducing a disease permitting MHC locus, they 
also introduced other BQ genes, which contracted the allelic diversity in the stock. 
The large number of intercross generations in an HS introduces inbreeding as 
well as complex family structures (private alleles) that, if not corrected for, lead to 
confounded associations and an excess of false positives43,44. Compared to a fully 
outbred population, an HS has some distinct advantages, however. Firstly, the allelic 
variation is controlled as it is limited by the eight founder strains. Thus, by genotyping 
the recombination breakpoints in the HS individuals, remaining variation can be 
inferred and instead of sequencing each HS individual, it is enough to sequence the 
eight founder strains. This concept was indeed proven in the rat HS (Baud et. al, Nature 
Genetics, accepted), which further showed that relatively few QTLs could be explained 
by a single variant. Secondly, alleles in an HS are not rare, as they are limited to the 
allele frequency in the founder strains. In an outbred population, common alleles 
become diluted as new alleles appear (through mutations and possibly recombinations). 
Hence, the allele frequency increases in an outbred population. Rare alleles that 
contribute to a trait are very difficult to control for and to map. The absence of rare 
alleles in an HS (this assumes that no new mutations appear after the stock has been 
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founded) increases statistical power to detect QTLs, and decreases thereby the 
requirement for large sample numbers.   
In summary, an HS offers superior mapping resolution compared to a 
conventional cross as well as more power to detect QTLs compared to an outbred 
population.    
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MAJOR HISTOCOMPATIBILITY COMPLEX &  
ANTIGEN PRESENTATION 
 
 
Introduction to the MHC  
 
The first complete sequence and gene map of the human major histocompatibility 
complex (MHC) was reported in 1999 by the MHC sequencing consortium45. However, 
the region was described 50 years earlier by George Snell, Jean Dausset and Baruj 
Benacerraf for which they earned the Nobel prize in 1980, although at that time the 
MHC was thought to consist of only histocompatibility genes46-48. The MHC was early 
recognized for its extreme diversity49, and for its association in many autoimmune and 
infections diseases. It is therefore not surprising that the MHC has remained as one of 
the most extensively studied regions in the human genome.   
Here, I discuss the genomic organization of the MHC, the distance between 
haplotype blocks as well as MHC class I and II antigen presentation, whereas the MHC 
association in autoimmune diseases will be discussed in a later chapter. First, however, I 
will introduce the somewhat confusing MHC nomenclature.  
 
 
The MHC nomenclature 
 
The MHC nomenclature is not straightforward. The term MHC is used in diverse ways, 
although typically referring to the continuous sequence that in humans spans ~4 Mb. 
Indeed, the word 'complex' in MHC refers to the early findings that genes in this region 
were clustered together and related by function50; however, this is not a universal 
feature of MHC in all species51. Dawkins et al. suggested, however, that in order to keep 
genes, gene families and region apart, the region should be referred to as the 'MHC 
region' rather than the shorter 'MHC'52. However, since the latter is more common, I 
will use MHC here when referring to the region and MHCI and MHCII when referring 
to those particular subregions.  
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Both classical and non-classical MHC genes in the rat are prefixed RT1, which is also 
the name of the region. What the abbreviation RT1 formally stands for is unclear, 
although Rat Transplantation locus 1 seems reasonable. In humans and mice, these 
genes (and the region) are called HLA (Human Leukocyte Antigen) and H2 or H-2 
(Histocompatibility locus 2), respectively. Moreover, according to standard 
nomenclature, all gene names are depicted in italic whereas regular fonts are used for 
protein names. Human gene names are spelled in capital letters (e.g. PSMB9) whereas 
rat genes names only have capital initials (Psmb9). Unfortunately, this consistency was 
not adopted in the manuscripts and papers included in this thesis, in particular not in 
Study IV, which uses 'chimeric' human and rat nomenclatures such as RT1-DQ and 
RT1-DR.    
 
 
Origin and organization of the MHC 
 
The MHC sequencing consortium determined the size of the human MHC to 3.6 Mb, 
with an average gene density of 1 gene per 16 kb45. This should be compared to 1 gene 
per 60 kb in the rest of the genome and 1 gene per 0.13 kb in the prokaryote E. coli53. 
This 'classical MHC' is flanked by extended MHCI (xMHCI) and xMHCII subregions, 
which together with MHCIII and the classical MHCI and MHCII subregions make the 
entire 'extended MHC' span about 7.6 Mb54. Approximately 420 genes are encoded 
within the extended MHC, of which 60% are expressed and 22% have immune-related 
functions. Within the classical MHC, roughly 40% have immune-related functions 
whereas all genes in the classical MHCII except RING3 encode components of the 
adaptive immune system.  
The second MHC sequence to be completed was the chickens' B locus55. The 92 
kb B locus is far more simple than the HLA locus with only 19 genes encoded, but still 
more complex than the MHC in frogs and sharks. MHC class I and II genes have been 
found in all jawed vertebrates examined so far but not in jawless vertebrates (e.g. 
hagfish, lamprey and sea urchin) or in invertebrates56. Sharks possess the simplest form 
of MHC, which have emerged some 520 million years ago. Sharks are also the oldest 
living species that have an adaptive immune system and a functional MHC-T cell 
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receptor (TCR) system, including the recombination-activating gene (RAG) that is 
necessary for immunoglobulin (Ig) and TCR rearrangement.  
Matsunaga et al. and others have suggested that the first prototypic MHC evolved 
in fish that have started to develop jaw-like structures and that the adaptive immune 
system evolved in the gastrointestinal area of these animals57. Hence, jaws, which 
probably have evolved as a consequence of a predatory life style, may have triggered the 
development of an adaptive immune system, which served to protect the animals from 
gastrointestinal infections57. However, the MHC as a region is older than the adaptive 
immune system and therefore does not seem to have evolved around class I and II 
genes. MHC genes such as NOTCH4 and RXRB are present also in organisms that lack 
an adaptive immune system, while other genes with apparently no immunological 
functions, such as RING358, have coevolved with class I and II genes since the speciation 
of jawed vertebrates. Hence, it is possible that the histocompatibility function of MHC 
is an adapted feature while the original complex had other functions, possibly as a 
system for sexual selection and avoidance of inbreeding59.  
 
 
Linked and unlinked MHC 
 
The MHCI and MHCII subregions are linked in most species but not in all. In the 
teleost fish, the MH class I, II and III loci (since the major histocompatibility genes in 
the fish are not part of a complex, the region is simply referred to as MH) are found on 
different chromosomes60,61. Interestingly, framework genes, such as TAP, LMP and 
RXRB, that in other species are located in the MHCII but functionally associated with 
MHC class I presentation are in pufferfish and zebrafish linked with the classical MHC 
class I genes62. In other species, such as the chicken and the quail55,63, MHC is separated 
into two clusters on the same chromosome, the B locus and the restriction fragment 
pattern-Y (Rfp-Y). It is likely that these two loci reflect a duplication of a larger segment 
in the avian MHC. Comparative studies have shown that both loci encode functional 
and polymorphic MHC class I genes and that these genes share a large degree of 
sequence homology. However, genes in the Rfp-Y locus appear to have more in 
common with MHC class Ib (non-classical) than class Ia genes64. This would argue 
more for an organization similar to the RT1 in the rat, where class Ia (RT1-A) and class 
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Ib (RT1-C/E/M) are separated by the MHCII and MHCIII loci. Also the swine has an 
unlinked MHC. The swine MHC, known as SLA, is positioned on chromosome 7 but 
MHCII and MHCI are separated by the location of the centromere. The SLA locus 
appears to be the only mammalian MHC locus that has unlinked MHCI and MHCII 
subregions65.   
 
 
The class I region  
 
Centromeric collinearity in the MHC begins with Kifc1 in rodents and humans66. This 
gene is located in the z block, which is proximal (near the centromere) to RT1-A and 
H2-K in rats and mice, respectively. The z block in humans accommodates the xMHCII 
locus, which, except for RXRB and TAPASIN (Tap binding protein, TAPBP), contains 
no immune related genes. MHC class I genes in rats and mice vary largely in copy 
numbers between different haplotypes67. The rat encodes 8 class I gene clusters, which 
are depicted RT1-A, -CE, -N, -M1, -M4, -M3A, -M3B, and -M268. The classical RT1-A 
locus, which consists of three genes (A1, A2 and A3), is the only MHCI locus that is 
located proximal to MHCII and MHCIII. The number of functional RT1-A genes vary 
between haplotypes, and the current assembly (RGSC 5.0), which is based on the RT1n 
haplotype, excludes RT1-A3. All remaining class I genes in the rat are non-classical 
MHCIb genes.  
The rodent MHC has a block of olfactory receptor genes at the distal (telomeric) 
end, which is substantially contracted in primates. In contrast, rodents lack the class I 
linked MIC genes that are found in primates, although a MIC related gene family called 
MILL has been mapped to chromosome 7 in mice69.  
The MHCI genes demonstrate a large degree of plasticity between species, which 
is not as evident for MHCII genes. In humans and chimpanzees, class I and MIC genes 
are organized as repeating units within duplicated blocks (so called evolutionary or 
frozen blocks). These blocks are serially connected as modules that have undergone 
significant diversifications, which have resulted in the immense heterogeneity that 
characterizes this locus. This diversification has further generated a large number of 
defective genes, which possibly explains why more than half of the genes in the MHCI 
are pseudogenes70. However, the module hypothesis does not fit with the expansion of 
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class I genes in the rat. Hurt et al., who published the first rat MHC sequence in 2004, 
noted similarities between genes in the RT1-A and the first telomeric RT1-CE clusters 
but not with other MHCIb genes66. Their data suggested that MHCIb genes in the rat 
were not generated through module duplications and they speculated that MHCI genes 
in rodents might have evolved independently following the speciation of mouse and rat. 
 
 
The class II region 
 
Duplicated modules are also apparent in MHCII; however, the orthologous 
relationships between mice, rats and humans for genes in MHCII and, in particular, 
MHCIII are more conserved in terms of gene order. Two larger blocks, known as 
epsilon (DP and DM) and delta (DQ and DR) have been identified in HLA52. Moreover, 
MHC class II alpha and beta genes appear in pairs except for DO, where the alpha and 
beta genes are separated by the location of RING3, DMA, DMB, PSMB8, PSMB9 and 
the TAP genes. The human MHCII contains 19 genes, of which 8 are pseudogenes. The 
number of pseudogenes differs between haplotypes71 and they appear to have evolved 
through duplications (mostly tandem) and have since then undergone diversifications 
and lost their function. It is possible that pseudogenes may have been maintained in 
this way to provide a source for generating new alleles by gene conversions72.  
However, not all module duplications lead to a loss of function. Paralogs have 
been shown for DQA, DQB and, in particular, DRB, while there is only one copy of 
DRA. This gene (DRA) is also monomorphic in both rodents and humans, which 
certainly reduces the total variation in the HLA-D locus substantially. It is known that 
certain DQ beta chains form very instable dimers with certain DQ alpha chains and 
these DQA and DQB alleles are therefore rarely found together on the same haplotype73. 
Since DQ and DR genes are in strong LD, a non-polymorphic DRA gene may therefore 
have been preferred in order to reduce the complexity in the MHCII by limiting the 
number of possible allele combinations.   
 At least four of the DRB genes are functional: DRB1, DRB3, DRB4 and DRB5. 
While little allelic diversity has been shown for the paralogous DRB3, DRB4 and DRB5, 
more than 100 alleles of DRB1 have been characterized and grouped into haplotypes 
DR1-DR10. These DR haplotypes combine different DRB1 alleles with specific paralogs 
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of DRB3 (DR3, 5 and 6), DRB4 (DR4, 7 and 9) and DRB5 (DR2), while there is no 
second DRB gene for haplotypes DR1, 8 and 10 74. The DRB loci are highly similar and 
it is therefore likely that they represent recent duplications. Both MHCII paralogs and 
pseudogenes are fewer in the rat, which to some extent reflect the lack of sequencing 
efforts. It is clear however that rats lack functional DP genes, and so far only a single 
MHCII paralog, RT1-Db2, has been reported66 and Study I.   
 
 
The class III region 
 
The centrally located MHCIII region is the most gene dense region in the human 
genome with 62 genes or 1 gene per 11 kb45. This region appears to have no 
pseudogenes, which makes it markedly different from MHCI and II. MHCIII contains 
further a number of highly conserved genes, such as NOTCH4, complement C4 and 
genes of the tumour necrosis factor (TNF) family that have members on other 
chromosomes66.    
 
 
Sequence heterogeneity in the MHC 
 
Early characterization of sequence polymorphisms in the MHC suggested that 
heterogeneity was focused to the hypervariable exonic sites (e.g. the second exons of the 
HLA-DR and HLA-DQ genes), and that non-coding heterogeneity was merely bi-
products of these highly variable exons. However, more recent genome sequencing has 
shown that polymorphism is prevalent throughout the region, albeit to a lesser extent. 
Why MHC display such diversity in non-coding DNA is still not clear. Certainly, this 
may reflect redundant sequence polymorphism, but the heterogeneity may also co-
localize with transcription regulatory sites. These sites may be close to (cis) or several 
kilobases away (trans) from the nearest gene. Significant efforts to map regulatory sites 
on a genome-wide level are currently ongoing75.  
The class I genes are the most polymorphic genes in the MHC and in the genome. 
The MH cluster of the fish seems to be the only exception where class II genes are more 
heterogenous than class I genes. In addition to the allelic variation in the MHC, 
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frequent gene duplications and copy number variations add to the overall 
heterogeneity76. Since also pathogens evolve rapidly, this extreme diversity may serve to 
increase the heterozygosity in the entire region and thereby the probability to clear an 
infection.  
 
 
Mapping recombination hotspots in the MHC 
 
The high gene density in combination with an extensive LD impair identification of 
causative variants in the MHC. However, the notion that LD is much stronger in the 
MHC than elsewhere in the genome is partially incorrect77. Strong LD exists in 
segments of approximately 22 kb throughout the genome78, including the MHC79. 
However, a complex pattern of LD between different segments seems to be unique for 
the MHC. These segments were described by Dawkins in 1982 as frozen haplotype 
blocks80,81. Dawkins postulated that these blocks acted as transposable elements that 
could form new haplotypes. Although recombinations occur between the blocks, they 
rarely, or never, occur within them. Thus, these blocks remained in the genome as small 
restricted units82, possibly conserved by a marked reduction in recombination activity. 
Such decline in recombination activity may result from mutations as discussed 
previously. Several of these blocks are apparent in the MHC, for example between HLA-
KE and HLA-DMA in the junction of xMHCII and MHCII, as well as between HLA-
DQB2 and HLA-DRB9. Why certain segments appear in LD is not known but cis-
interactions between linked segments may have had selective advantages. 
In a number of studies published in the beginning of the 20th century, Cullen et 
al. and Jeffreys et al. described the recombination rate in the HLA using single-sperm 
cell typing21,83,84. Their studies showed that recombination hotspots in the MHC were 
unevenly distributed and that the recombination rate varied greatly between different 
individuals. Their data are therefore consistent with the notion that specific sequence 
motifs may accelerate the recombination activity. Cullen et al. identified six major 
hotspots within an interval of 3.3 Mb as well as several 'colder' regions, which largely 
overlapped with the distribution of frozen haplotype blocks as postulated by Dawkins80. 
The MHCIII showed overall lower recombination activity than MHCI and MHCII, 
which is in keeping with the conserved gene order that characterizes this region in 
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many species. Intervals with particularly high recombination activity were found within 
DPB1 to RING3 (Brd2 in rat), DRA to TSBP (Tesb in rat) and BAT2 to LTA21. 
 
 
MHC class II expression is controlled by CIITA 
 
The transcription factor CIITA (class II transactivator) is a chief regulator of MHC class 
II transcription85. CIITA belongs to the NOD-like receptor (NLR) protein family, which 
trigger innate immune responses, for example upon exposure to bacterial cells wall 
components86. CIITA was the first NLR to be characterized, and while certain NLRs, 
such as NLRP3, are constituents of the inflammasome87, the function of CIITA appears 
to be specific for MHC regulation.  
Mutations in the MHC2TA gene that severely affect the expression or function of 
CIITA result in a rare form of immunodeficiency known as bare lymphocyte syndrome 
(BLS)88, a disorder that has served as a prototypic model for the study of MHC 
regulation in humans85. Mutations in MHCII-transcription factors RFXANK, RFX5, 
RFXAP are also associated with BLS, while genes in the MHCII locus itself are not 
associated.  
That CIITA is a master regulator of MHCII expression is demonstrated by its 
wide role in both constitutive and inducible MHCII expression73, as well as by its 
impact on both classical and non-classical (DM and DO) MHC genes88. CIITA does not 
possess a DNA-binding domain itself and is therefore dependent on other transcription 
factors89. Cis-regulating promoter regions in both MHCI and MHCII genes share 
distinct consensus sequences containing W/S, X1 and X2 motifs as well as a Y-box, 
which is a canonical CCAAT box, which promote binding of transcription factors RFX, 
CREB/ATF1 and NF-Y90. These form together with CIITA the MHC enhanceosome91. 
The regulation of CIITA expression occurs mainly on transcript level, which is 
controlled by four cell-specific promoters entitled P1-P4. The P1 promoter is dendritic 
cell (DC) specific and drives the expression of the longest CIITA isoform92. The P1 
promoter is also associated with the highest expression of the MHC2TA gene and the 
expression of MHCII in DCs, at least in immature cells, is therefore higher than in any 
other MHCII bearing cell93. 
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It is unclear to which extent CIITA also can regulate the expression of MHCI genes, 
although a few studies suggest that it does88,94. However, since the expression of CIITA 
is confined to lymphocytes and APCs, it is unlikely that CIITA is responsible for the 
constitutive expression of MHCI73. That CIITA is essential for MHCI expression is 
further challenged by the normal level of MHCI expression in BLS patients85. Recently, 
another NLR protein, NLRC5, was shown to operate as a regulator of MHCI 
expression95. This proteins, which has no influence on MHCII expression, has further 
been shown to control the expression of the non-classical MHCIb gene HLA-E as well 
as genes involved in class I antigen presentation and processing, such as β2M, LMP2 
(Psmb8) and TAP195. RXRB is another transcription factor that regulates MHC class I 
gene expression. This gene is, in contrast to NLRC5, encoded within the MHCI 
subregion96. 
 
 
Antigen presentation: MHC class II 
 
Professional antigen-presenting cells (APCs), which include DCs, macrophages and B 
cells, express MHCII constitutively and possess efficient mechanisms for 
internalizations of proteins and other macromolecules. In contrast, these mechanisms 
are relatively poor in non-professional APCs, which are cells of epithelial origin, such as 
keratinocytes, that express MHCII only after activation.  
MHCII molecules exit the endoplasmic reticulum (ER) in a nonameric complex 
consisting of three MHCII molecules surrounding a core of three glycoproteins known 
as invariant chains (li)97,98. The association with li has at least three purposes; firstly, the 
li protects the empty pocket from being pre-maturely loaded until the complex reaches 
the late endosomal compartment; secondly, a domain in the li directs the complex to 
the endosomal compartment and, thirdly, li stabilizes the complex and prevents it from 
degradation99. li:MHCII complexes enter late endosomal compartments known as 
MIICs (MHCII compartments), after which the li is degraded by resident MIIC 
lysosomal proteases such as cathepsin S and cathepsin L100. Within the peptide binding 
groove stays a small li-derived peptide called CLIP (class II-associated invariant 
chain)101. This peptide competes with other peptides in the MIIC for binding to MHCII. 
Hence, the purpose of CLIP is to ensure that low-affinity peptides are excluded from 
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the binding groove. The non-classical MHCII molecule HLA-DM is essential for the 
exchange of CLIP peptides in the MIIC102,103. DM stabilizes the open conformation of 
the pocket until a stable interaction with a new peptide can form104,105. Indeed, the 
exchange of CLIP peptides is markedly reduced in DCs knocked-down for HLA-DMB, 
which results in increased levels of CLIP:MHCII complexes on the cell surface106. A 
second non-classical MHCII chaperone known as HLA-DO associates with DM during 
the transport from ER to the MIIC107. Similarly to li, DO prevents pre-mature loading 
of MHCII until the complex has reached the MIIC. Although different functions have 
been ascribed to DO, its major role is to block the function of DM and, hence, regulate 
the exchange of CLIP peptides. It has been postulated that DO looses its inhibiting 
capacity in the slightly acidic environment that is present in the MIICs108. However, in 
two recent studies, Guce et al. and Yoon et al., showed by X-ray crystallography and 
mutagenesis that HLA-DO in fact acts as a competitive inhibitor of HLA-DM for the 
substrate MHCII109,110.  
Peptides bind differently to MHCII and MHCI molecules. The peptides that fill 
the grooves of MHCII molecules protrude from each end, while peptides are entirely 
contained within the groove of MHCI molecules. The MHCII pocket is shaped by the 
polymorphic external domains !1 and "1, which form two antiparallel helical loops as 
well as a floor of eight beta strands. Amino acids in the groove form hydrogen-bonds 
(as well as other chemical interactions) with the backbone and side chains of the 
encompassed peptide111,112. The nine amino acid residues of the peptide that fit within 
the groove are numbered (from the N-terminal end) p1-p9. The stability of the 
interaction is mainly dependent on peptide side chains at position p1, p4, p6 and p9 
that can bind strongly to structures (pockets) within the groove. The MHCII residues 
that occupy these positions can help to identify specific binding motifs, i.e. peptides that 
fit particularly well into the pocket113,114. 
 
 
Antigen presentation: MHC class I 
 
Proteins of intracellular origin are degraded by cytosolic and nuclear proteases for 
transport to the ER and subsequent loading onto MHCI molecules. Although the 
process shares several features with MHCII presentation, the process of loading, and 
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the compartment, in which this takes place are entirely different. Many of the peptides 
that are presented in the context of MHCI are derived from proteins that are at the end 
of their life-cycle. However, a system entirely devoted to presentation of only ‘worn-out’ 
proteins would be very vulnerable to viral infections. Therefore, many, if not most, of 
the peptides that are presented by MHCI derive from proteins that are degraded 
immediately after synthesis. Thus, the MHCI peptides that are displayed on the cell 
surface are derived from proteins that are currently being translated in the cell. A part 
of the rapidly degraded proteins are DRIPS (defective ribosomal products), which result 
from defective transcription or translation or from protein mis-assembly. MHCI 
peptides may also be generated by unconventional transcriptional mechanisms. Such 
peptides may stem from frame-shifted sequences, introns, and 5' and 3' untranslated 
regions. CD8 T cells must therefore screen an extreme diversity of peptides in order to 
identify the few that are non-self.  
Peptides are funnelled from the cytosol to the ER via the transporter associated 
with antigen processing (TAP)115,116. Inside the ER, TAP associates with an additional 
four members of the peptide-loading complex (PLC): tapasin, calreticulin, ERp57 and 
the MHC class I molecule. Although peptides are trimmed by the proteasome before 
entering the ER, an additional aminopeptidase within the ER known as ERAAP is 
important for the finale shaping of the class I cargo. ERAAP was first identified by 
Serwold et al. who showed that class I expression is greatly reduced on the cell surface 
in the absence of this enzyme117. Peptides that do not fit the binding groove of MHCI 
after trimming is shuttled back via the translocon Sec61p for destruction in the 
cytosol118 or reentering into the ER via TAP119. 
Tapsin influences the stability of the MHCI:peptide complex, the translocation of 
peptides to the ER and the levels of Tap in the ER membrane120, albeit the dependancy 
of tapasin varies greatly between different MHCI alleles121. The stoichiometric 
relationship between tapasin and MHCI in the PLC is 2:1122 and each MHCI molecule is 
associated with one molecule of β2-microglobulin (β2m). The tapasin molecules 
associate with TAP via their ER transmembran domain whereas they are covalently 
bound to ERp57 via a disulfide bridge123. The role of ERp57 in the PLC appears to be to 
stabilize the interaction with MHCI. The recruitment of MHCI to the PLC is normal in 
B cells deficient for ERp57124, while in the absence MHC class I dissociates more rapidly 
from the PLC. Hence, several components of the PLC are responsible for bringing the 
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MHCI molecule into close contact with the TAP transporter and to retain it there long 
enough for peptides to be loaded. Once a stable interaction between peptide and MHCI 
has formed, the loaded MHCI dissociates from the PLC and translocates to the cell 
surface. 
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AUTOIMMUNITY 
 
 
Introduction to autoimmunity 
 
MHC is, without comparison, the strongest genetic risk factor for autoimmune and 
infectious diseases. Albeit some diseases, such as ankylosing spondylitis and psoriasis 
vulgaris have been convincingly associated with class I genes and yet others with class II 
genes, a large number of these diseases appear to be associated with multiple alleles in 
several different subregions of the MHC. In rheumatoid arthritis, as well as in other 
common autoimmune diseases, alleles in MHCII appear to be the major risk 
components, which suggests that a breakdown in T cell tolerance is a major trigger in 
the pathogenesis of these diseases. Here I discuss the role of MHC genes in 
autoimmunity and the etiology and pathology of rheumatoid arthritis. 
 
 
MHC genes in autoimmunity 
 
The complexity of the MHC hampers identification of disease causing variants. The 
reason for this complexity is the high degree of genetic variation and extensive LD that 
exists between alleles, or between segments of alleles. The large proportion of  rare 
MHC alleles, copy number variants, and the diversification of paralogous genes have a 
great negative impact on mapping resolution and the differentiation between haplotype 
and allele associations. Nevertheless, a number of predisposing variants have been 
proposed for a large number of autoimmune diseases.  
In 1967, Hodgkin’s lymphoma became the first disease to be associated with 
MHC, when HLA-B antigens were found to be at increased frequency in these 
patients125. The MHC association in multiple sclerosis (MS), a chronic inflammatory 
demyelinating disorder, remains the most reproducible association that has been 
identified in an autoimmune disease so far126. This association, which is directed to the 
HLA-DR2 haplotype, was discovered as early as in 1972127. However, the extensive LD 
in the DR2 haplotype has made it difficult to determine whether the risk is conferred by 
DQB1*0602 or DRB1*1501, although recent studies have favoured the latter128. Linked 
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MHCI alleles, in particular HLA-A*0201 and HLA-A3, may further contribute to the 
disease association in MS. In addition, recent meta-analysis have shown an association 
for haplotypes DR3 and DR4129.  
In rheumatoid arthritis (RA), which is distinguished by chronic inflammation in 
small and large joints (see below), the total variance explained by heritability is about 
50%, of which HLA explains 36%130,131. Markers in HLA-DRB1, in particular at position 
11, which correspond to the β-sheet floor of the antigen-binding groove, account for 
the strongest association130,132. Significant associations have also been found for position 
71 in this protein when adjusting for the effect in position 11 and for 74 when adjusting 
for the effects in both 11 and 71. The association to positions 71 and 74 in DRB1 is 
consistent with Gregersens' shared epitope hypothesis133, which stated that a sequence 
of amino acids in the third hypervariable region of DRB1 (70 Q/R-K/R-R-A-A 74) was 
common in patients with RA. When all effects associated with DRB1 are neutralized, 
Eyre et al. and Raychaudhuri et al. found significant associations for HLA-B (position 
9) and, after adjusting for HLA-B, also HLA-DPB (position 9). The combined effect of 
these five positions account for most of the MHC association in a subset of patients 
with antibodies to citrullinated peptides132.  
A few MHCII alleles appear to be overlapping between different types of 
autoimmunity; however, the vast majority of associated alleles are not. This disease 
specificity may argue for tissue-specific antigen presentation in autoimmunity. It has 
therefore been of major interest to characterize the ligandome of different MHCII 
alleles 134-137.  
 
 
Rheumatoid Arthritis - a heterogenous disease 
 
The strong HLA association in RA to DRB1 as well as to other MHCII genes and to 
MHCI, provide important insights into the disease etiology. Other genetic associations 
to PTPN22, STAT4, IL6R, PADI4 and TRAF1-C5130,138-141 have also contributed to 
uncover disease related mechanisms, although their effects on disease  are relatively 
small (odds ratio, OR<2) compared to MHCII (OR>6). The most strongly associated 
SNP in IL6R, for example, correlates with the levels of circulating IL-6R, a cytokine 
receptor that is a promising therapeutic target in RA. The associated genes highlight 
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molecular pathways in both the adaptive and innate immune system, and the 
association to PADI4, a citrullinating enzyme, suggests an important role for antigen 
modifications in RA. Accumulating data suggest that the presence of anti-citrulline 
protein antibodies (ACPAs) as well as IgM and IgA rheumatoid factors (RFs), which 
are directed against the Fc fragment of IgG, are highly correlating with shared epitope 
alleles of DRB1 and disease associated variants of PTPN22142,143. This suggests that 
seropositive RA, which is the most common and most severe form of RA144, constitute a 
distinct disease subset with an etiology that is more related to defective adaptive 
responses145. That patients respond differently to treatments with biological drugs, in 
particular the cytokine or cytokine receptor inhibitors directed to TNF (etanercept and 
others), IL-1 (anakinra) and IL-6R (tocilizumab), but also to B cells (CD20 
[rituximab]), support the notion that RA is a heterogenous disease146. Hence, the 
genetic makeup and/or environmental stimuli may trigger different disease 
mechanisms in different patients and to use genetic typing to personalize the treatment 
for these patient may be a plausible scenario in the future.  
 
 
T cells are expendable in established RA 
 
The strong association to DRB1 agues for an important role of MHCII:TCR 
interactions in RA, and highlights the relevance of CD4 T cells in the disease. That T 
cells infiltrate the synovia in RA was shown nearly 40 years ago147. Infiltrating T cells 
consists of CD4 and CD8 subsets. However, while CD8 cells are relatively sparse in the 
synovia, the CD4 cells are numerous (~50% of the cells in the RA synovia) and appear 
to be pre-activated, as demonstrated by their defective IL-2 response148,149. However, to 
which extent these T cells contribute to the pathogenicity in RA is still unclear. It seems 
reasonable that T cells play an important role in undifferentiated RA (before diagnosis), 
which would be consistent with the presence of ACPAs of IgG isotype years before the 
clinical disease onset150,151. Furthermore, studies by Moreland et al. and others152,153 have 
shown that patients treated with chimeric antibodies to human CD4 (cM-T412) in 
combination with methotrexate (the most commonly used DMARD in RA) show no or 
minor clinical effects of the treatment, despite being severely lymphopenic. The 
outcome of the clinical trails with alemtuzumab, a CD52-specific monoclonal antibody, 
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were also disappointing in RA despite showing promising effects in MS154. These 
studies may suggest that T cells do not contribute to the perpetuation of RA. 
 
 
The articular disease 
 
The synovial lining, which encompasses the joint cavity, consists of macrophage-like 
synovial cells and synovial lining fibroblasts, also known as fibroblast-like synoviocytes 
(FLS). This thin hypocellular layer, which has no epithelium or basement membrane, 
becomes hyperplastic in the inflamed joint. Hyperplasia triggers terminally 
differentiated macrophage-like synovial cells to produce cytokines, chemokines and 
growthfactors and to upregulate MHCII and co-stimulatory molecules. This, in turn, 
stimulates FLS to produce matrix metalloproteinases, which promote articular damage 
and cartilage destruction155. These activated FLS display a transformed phenotype. 
When isolated from RA, but not from osteoarthritis patients (OA), FLS demonstrate 
increased invasiveness after implantation along with human cartilage in SCID mice156. 
The FLS share other features with tumour cells, in particular the ability to grow in 
suspension157 and the resistance to apoptosis. Importantly, these activated FLS can 
spread between joints and thereby transmit inflammation to unaffected tissue, which 
may explain the polyarthritic manifestation that is typical for RA. However, the disease 
might also emerge from the bone as a consequence of osteoclast activation leading to 
bone erosion and then spread to the joint to initiate an activation of FLS158. Inhibition 
of osteoclast activation may prevent bone destruction, although it has little or no effect 
on joint inflammation159. Moreover, the subcortical bone marrow is subjected to T cell 
and B cell infiltrates, suggesting that the bone marrow is an additional compartment in 
the disease process of RA160. 
 
 
Breaking tolerance 
 
While the series of events that take place in the arthritic joint (i.e. overproduction of 
cytokines that sustain the chronic synovitis and infiltration of immune cells) are fairly 
well delineated, it is still unclear why T cell and B cell tolerance is breached in the first 
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place. The association to PTPN22 suggests that the threshold for T cell activation may 
be affected. The associated variant (R620W) in PTPN22 is a gain of function mutation 
that may promote negative selection of autoreactive T cell clones in the thymus161. The 
fact that PTPN22 show a similar association in a number of autoimmune diseases 
further supports that this gene regulates T cells on a general level rather than acting in a 
disease specific manner162. It is not clear whether T cells in fact are primed within the 
synovial compartment. The synovial milieu contains certainly all cytokines necessary to 
activate T cells, such as such as IL-1, IL-6, IL-12, IL-23p19 and TGF-", as well as both 
myeloid and plasmacytoid DCs necessary for the activation of naive T cells163. Once the 
cartilage damage is initiated, new epitopes provide a rich source of immune stimuli for 
T cell priming. However, it remains to be shown which autoantigens these are. T cell 
response to both cartilage (collagen type II) and ubiquitous protein antigens have been 
described in RA but to which extent these antigens are important for disease priming is 
not known164-166.  
Autoimmunity ensues when both central and peripheral tolerance mechanisms 
fail. Expression of tissue specific antigens in the thymic medullary epithelium ensures 
that T cells are properly tolerized when leaving the thymus. Those autoreactive T cells 
that escape negative selection are maintained in a non-responsive state by peripheral 
regulatory T cells.  
Self-peptides that provoke an autoreactive T cell response may have either high or 
low affinity. High affinity is consistent with the finding that most, if not all, of the 
MHCII association in RA can be explained by a few key residues in the MHCII binding 
groove. These high-affinity peptides may be absent from the ligandome of thymic 
epithelial cells but exist in the periphery or emerge as consequent of tissue damage. 
Peptides that bind strongly to MHCII may also increase the risk of triggering low-
affinity autoreactive T cells that have escaped negative selection. 
    Alternatively, since central tolerance to peptides that have been modified in the 
periphery might be poor or absent, such peptides may provoke T cell activation despite 
binding weakly to MHCII. Moreover, since these peptides are not part of the natural 
peptide repertoire, they may be recognized by high-affinity T cells in the periphery as 
truly foreign antigens. Compared to high affinity peptides, these peptides may be 
relatively common, at least in the tissue from which they are derived. One such tissue-
specific peptide that is modified in its peripheral compartment is the immunodominant 
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T cell epitope on collagen type II (CII). This peptide is immunogenic in mice in its 
glycosylated but not in its non-glycosylated form. However, whether glycosylation is a 
post translational modification that occurs only in the periphery on collagen is not 
known, nor is it known whether CII at all is presented in the thymus, although the 
tolerance to non-glycosylated peptides would suggest so165.  
 
 
Th effector cells 
 
RA has recently changed from being a prototypic Th1 disease to be more associated 
with a Th17 phenotype. This change is largely reflecting the pathogenic role of Th17 
cells in rodents (discussed below), while there is still little support for either subset in 
human RA. IFN-#, a signature cytokine for Th1, which is indispensable for clearing 
intracellular pathogens, is found in very small quantities in the RA synovial fluid, 
suggesting that IFN-# may not be necessary for the activation of synovial 
macrophages167. Moreover, administration of recombinant IFN-# to patients with RA 
does not significantly change the disease course168. However, the association to STAT4 
in RA, which is a Th1 associated transcription factor, does implicate a role for Th1 cells 
in the disease. The first study on Th17 cells in RA was performed by Chabaud et al. in 
1999. They demonstrated that synovial membrane tissue from RA, but not OA, 
produced large amounts of IL-17. They further showed expression of IL-17 in 
perivascular T cells, although they did not quantify Th17 cells directly169. Shen et al. 
measured Th17 and Th1 cells in the SF from patients and found ~1% Th17 cells and 
~10% Th1 cells. They could further show that Th17 cells were increased in SF of 
patients and that the frequency of Th17 in the PBMC compartment correlated with 
CRP, an acute-phase protein that is increased in RA170. Church et al. compared Th1 and 
Th17 cells in the SF, synovial membrane and blood from patients and controls and 
found comparable levels of Th17 cells in SF and blood (~1-2%) and significantly more 
Th17 PBMCs in the blood of healthy controls compared to patients. However, they 
detected very few Th17 cells in the synovial membrane, which is inconsistent with 
Chabauds' study171. Finally, Yamada and colleges showed that the frequency of Th17 
cells in the blood was similar in patients and controls and did not correlate with the 
DAS28 (a measure of disease activity in RA). In addition, they showed that the 
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frequency of Th17 cells was decreased in the SF compared to blood, while the frequency 
of Th1 cells was increased in the SF172. It is reasonable to assume that much of the 
reported discrepancy for Th1 and Th17 cells in RA pertains to antirheumatic therapy, 
in particular the use of TNF inhibitors and other biological drugs. 
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ANIMAL MODELS OF RA 
 
 
Introduction to animal models 
 
Animal models provide tools to identify disease mechanisms and targets for clinical 
interventions in humans. However, it is debated to which extent they manage to do so. 
Experimental models for RA have been criticized for not reflecting the diversity of 
human disease. These arguments have gained relevance in the post-genomic era when 
patients can be divided into disease subsets according to MHCII alleles and, more 
recently, anti-citrulline response. However, an experimental model needs to be 
reproducible and present a phenotype with reasonable frequency (i.e. the disease needs 
to be penetrant). The vast majority of models therefore use active immunizations with 
tissue-specific antigens in combination with aggressive adjuvants and, often, 
supplements of bacterial components. The stability is further reinforced by an extreme 
genetic homogeneity. Moreover, the microbiome of rodents, in particular in those that 
are born and raised in a clean environment, differ substantially from humans. Next to 
the genetic makeup, the microbiome is probably the most important conditioner of the 
immune system.  
To combine information from different animal models can, at least partially, 
compensate for these flaws. In general, models that are independent on exogenous 
antigens (i.e. adjuvant models) and spontaneous models, such as the K/B×N and SKG 
models in the mouse173-175, are to be preferred over models that are actively induced 
with tissue-antigens and strong adjuvants. Moreover, models that are not strictly strain 
dependent are more likely to capture more features of human autoimmunity and 
models that operate across species is of course more suitable than models that are 
species-specific. I discuss here three models in rats and mice; pristane-induced arthritis 
(PIA), PIA transfer and collagen-induced arthritis. The first model is an adjuvant 
model, which is free from exogenous antigens. The second model is induced by 
adjuvant primed and ex-vivo restimulated T cells while the third model is antigen 
induced.   
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Intraperitoneal injections of pristane induce lupus and arthritis in mice 
 
Adjuvants containing mineral oils, mineral oils themselves and certain alkenes, such as 
pristane (2,6,10,14 tetramethylpentadecane) are suitable for induction of 
plasmacytomas (malignant plasma cells) in mice. These agents, which cannot be cleared 
efficiently by the immune system, induce chronic granulomatous reactions that 
stimulate tumour growth. The tumour inducing effect of these agents is dependent on 
IL-6, a cytokine that is found in high concentrations in the circulation of patients with 
RA176. Indeed, in addition to tumours, Potter and Wax reported in 1981 that repeated 
intraperitoneal injections of large volumes (0.5 mL or more) of pristane induced 
arthritis in Balb/c mice. The arthritis appeared several months after the first injection in 
~60-80% of the mice but rarely spread beyond ankle and wrist joints177. Even if a 
relapsing disease was observed in a few mice, the arthritis was in general self-remitting. 
Histological analyses of affected joints in mice injected with pristane have shown 
neutrophilic infiltration, cartilage erosion and pannus formation178 and serological 
analyses have shown increased and disease correlating levels of RF179. Pristane-induced 
arthritis in mice is associated with haplotypes H2q, H2d and H2r, as well as with non-
MHC genes179. Injection of pristane may also induce the formation of ectopic lymphoid 
tissue and production of lupus antibodies180-182 and the model has therefore been 
suitable for the study of lupus (SLE) in mice.  
 
 
Intradermal injection of pristane induces chronic arthritis in rats 
 
The rat model of pristane-induced arthritis (PIA) shares several features with the 
mouse model; however, in the rat protocol pristane is administrated intradermally as a 
single small dose (typically 100-200 µl) rather than intraperitoneally. The model was 
described for the first time in 1996183, although at the time it was known that both 
complete and incomplete Freund's adjuvant (i.e. with and without Mycobacterium 
tuberculosis, respectively) induced arthritis in rats184,185. However, PIA, in contrast to 
these models, is a chronic relapsing disease, which makes it significantly more useful as 
a model for RA186.  
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The DA and LEW strains are susceptible to PIA while the E3, ACI and F344 
strains are resistant187. A large number of highly significant QTLs have been shown to 
be associated with arthritis onset, severity and chronicity in PIA, and many of these 
overlap with QTLs identified in collagen-induced arthritis38,39,188-191. However, with a 
few exceptions (Pia4, harbouring the Ncf1 gene, being the most prominent192), these 
loci represent large chromosomal intervals with many plausible gene candidates. As 
discussed in a previous chapter, congenic mapping to position causative genes has been 
extremely laborious, in particular in regions with many genes and extensive LD. Hence, 
to which extent susceptibility genes in PIA overlap with identified loci in RA is still not 
known. An association to the MHC, similar to the one found in mouse PIA, has been 
described also in the rat38; however, an association with MHCII genes has so far not 
been published (Study II).  
Immunization with pristane in DA rats leads to elevated levels of acute phase 
proteins, in particular !1-acid glycoprotein (AGP), as well as RF193, IL-627 and IL-1"194. 
Both IL-6 and AGP levels decrease during the chronic phase of the disease. A 
correlation has been shown in RA for CRP and IL-6, which is one of several cytokines 
that can promote synthesis of acute phase proteins in the liver195. Elevated CRP levels is 
also a classification criteria for RA196. Extra-articular manifestations, such as 
splenomegaly, which have been observed in the mouse model, have not been reported 
in the rat, although ankylosis in the tail is frequently seen in DA but not in LEW rats27. 
Depletion of CD4 T cells prior to immunization effectively prevents development of 
PIA183. T cell dependency has also been shown in other adjuvant models197 and in 
collagen-induced arthritis (CIA)198. However, while T cells do not contribute to the 
disease progression in CIA, they appear to do so in adjuvant arthritis (induced by 
complete Freund's adjuvant)198 and, possibly, in PIA183. Neither depletion of CD8 T cells 
nor #$T cells influence the development of adjuvant arthritis199,200, and at least CD8 
depletion does not prevent arthritis development in DA rats immunized with pristane 
(Tuncel et al., unpublished data).   
An MHCII restriction has been shown in PIA transfer for both RT1-D and RT1-
B molecules201. However, these experiments were based on administration of whole 
antibodies and the effect on arthritis may not be limited to the blocking capacity of the 
antibodies. At least the RT1-D antibody has opsonizing properties and injection into 
rats leads to a substantial cell death of MHCII positive cells, and possibly also T cells202 
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(Tuncel et al. unpublished data). Hence, the MHCII restriction cannot easily be 
interpreted from these studies. However, we have now determined the MHCII 
dependency in the induced model using F(ab')2 fragments of RT1-D and RT1-B specific 
antibodies (Study II).  
It is possible that intradermal or subcutaneous injections of oil cause cell death in 
the draining lymph nodes where the oil accumulates194,203. Necrotic cells may certainly 
provide a rich source of antigens for T cell activation but it seems unlikely that those 
antigens would drive a tissue-specific immune response. However, release of DNA into 
the pericellular space may promote activation of APCs by nucleic acid-sensing toll-like 
receptors (TLRs). Nucleic acids may indeed promote activation of T cells204. Pristane 
may also be incorporated into the plasma membrane of APCs and other cells, leading to 
an unspecific immune activation and subsequent release of pro-inflammatory cytokines 
such as IL-6 and IL-1. Adjuvanticity has been shown to be strictly associated with the 
length of the hydrocarbon chain and appears to be strongest in hydrocarbons of 
intermediate length (C15-C20)205. Lipophilic hydrocarbons can disturb the integrity of 
membranes in microorganisms and increase the permeability for ions206. Indeed, an 
influx of ions, in particular Ca2+, would have profound impact on cellular activation207.  
Innate responses appear to be essential for the induction of autoreactive T cells in 
PIA. Acute phase responses, which are induced by innate cells, are raised prior to 
disease onset and the levels of AGP in undifferentiated PIA correlate with disease 
progression and neutrophilia in immunized rats208 (Tuncel et al. unpublished data). 
This suggests that IL-6 and possibly also IL-1", which both increase upon pristane 
immunization, may be essential for the induction of T cells response, and at least IL-6 is 
also found in the murine PIA model. Pristane may also facilitate uptake of cartilage-
derived antigens from the lymph; however, since pristane lacks the emulsifying capacity 
of Freund's adjutant, pristane cannot encapsulate antigens into micelles. 
Whether exposure to mineral oils and other adjuvants is a risk factor in RA is still 
debated209. Squalene, which is a cholesterol precursor that is arthritogenic in DA rats, is 
a common constituent in cosmetics and in vaccine adjuvants and several cosmetic 
products induce arthritis when injected intradermally in DA rats209-211. Moreover, 
percutaneous (on the skin) applications of incomplete Freund's adjuvant has been 
shown to induce arthritis in DA rats, although only on abraded skin212. A Swedish case-
control study showed that men suffer 30% increased relative risk of developing RA if 
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exposed to mineral oils213, while mineral oils in skin products does not appear to confer 
risk to RA209. Moreover, a long-term follow-up study of Army recruits who received 
influenza virus vaccines emulsified in incomplete Freund's adjuvant (which is no longer 
FDA approved for use in humans) found no evidence for increased incidence of 
autoimmune disease214.  
 
 
PIA transfer 
 
Pristane as well as incomplete and complete Freund's adjuvants can be used to prime T 
cells for passive and adoptive transfers. The manifestations of the transferred disease 
resemble in large the induced model; however, the transfer of pristane-primed cells 
does not induce a chronic disease, at least not in immunocompetent hosts. In general, 
passive transfer of cells from complete Freund's adjuvant-primed donors to normal 
immunocompetent rats is not possible, although at least one study has shown the 
opposite215. An exception is passive transfer of thoracic duct (TD) cells, which consists 
of highly activated cells and presumably a larger proportion of arthritogenic T cells216. 
In addition, arthritis can be transferred passively from CFA primed rats to 
thymectomized and irradiated hosts217, while irradiated, non-thymectomized rats do 
not develop arthritis when transferred passively with pristane-primed cells (Tuncel and 
Holmberg, unpublished data). A standard protocol has been developed for adoptive 
PIA transfer, in which pristane-primed T cells are stimulated ex-vivo with 
Concanavalin A (ConA) for 65 hrs before intravenous transfer into naive syngenic 
hosts (Tuncel et al., manuscript in preparation). We and others have previously 
reported optimal conditions for priming and re-stimulation in PIA and adjuvant 
transfer models201,217; however, a standardized protocol for PIA transfer has so far not 
been published. At least in our hands, the severity and duration of arthritis are 
dependent on a number of aspects, of which the age of the recipient, the extension of 
the priming, the route of the injection and the source of the cells are the most 
important, whereas the number of transferred cells, at least when injecting 
intravenously, has little impact on the severity (Tuncel et al., unpublished data).    
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Collagen Induced Arthritis 
 
Collagen-induced arthritis is a classic model of RA and although first reported in rats218, 
it is more commonly used in mice219. The rat model of CIA is typically induced with 
autologous rat CII, although other articular collagens, such collagen type XI, can also 
induce arthritis220,221. Mycobacterial supplements in the adjuvant or booster injections 
are not needed in the rat model but they are typically necessary in the murine model. 
Mice are in addition fairly resistant to immunization with autologous CII and the T cell 
response in mouse CIA is therefore directed to a heterologous antigen, while the 
antibody response is directed to both the inoculated and the endogenous collagen. The 
manifestations in the joints are similar between CIA and the oil-induced models, with 
the major infiltrating cells being neutrophils and CD4 T cells and, to a less extent, CD8 
T cells185. However, while PIA and other adjuvant models preferentially affect larger 
joints, such as the ankle, CIA targets more the smaller joints in the digits. Mouse CIA 
lacks several distinctive features of RA, such as RF, ACPAs and a female 
preponderance222, and the disease course is typically more monophasic than relapsing-
remitting as in PIA. The arthritogenic response is predominantly, if not entirely, 
directed to collagen type II and even if CII reactive antibodies are present in patients 
with RA220, their pathogenic contribution is still elusive. Nevertheless, autoantibodies 
appear to play an important role in RA pathology, which in particular treatments with 
rituximab has shown, and CIA therefore fulfils an important role as an antibody driven 
model.  
 
  
T cell polarization in experimental arthritis 
 
The discovery of IL-23 by Oppmann and colleges in 2000 223 challenged the prevailing 
perception that autoimmune disease was caused by Th1 cells. The new culprit was the 
Th17 cell and its signature cytokine IL-17. In the end of 1990s, several studies had 
shown that IFN-γ or IFN-γ receptor knockout mice developed more severe arthritis 
than their wildtype littermates. The absence of IFN-# was postulated to promote IL-4 
dependent Th2 immunity and, hence, production of autoantibodies224,225. However, 
many of the findings at the time were inconsistent. Boissier, for example, showed that 
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IFN-# neutralizing antibodies could prevent the development of CIA in DBA/1 mice 
when administrated during the priming phase, while the same treatment had the 
opposite effect when performed on established disease226. Yet other studies showed that 
repeated injections of recombinant IL-12, a cytokine released by macrophages and DCs 
to stimulate the production of IFN-#, delayed the onset of CIA in the same strain227.  
Oppmanns' finding of IL-23 clarified much of this discrepancy. When searching 
sequence databases for members of the IL-6 family, they identified a novel cytokine 
they named p19. This cytokine was found to be distantly related to the p35 subunit of 
IL-12. The p19 cytokine itself had no biological activity but it combined with the p40 
subunit of IL-12 to form a composite cytokine. They termed this composite cytokine 
IL-23 and could show that it activated STAT4. It further had a strong effect on memory 
T cells in both mice and humans. Hence, since most of the IFN-# deficient mice were 
mutated in the p40 subunit, the resulting models were deficient in both IFN-# and IL-
23. Targeting the p40, p35 and p19 subunits independently showed that IL-23 rather 
than IL-12 was essential for the induction of autoimmunity in several models228,229. In 
arthritis, mice lacking only IL-12 (p35) were shown to develop more CIA while mice 
lacking only IL-23 (p19) were completely protected230. It was further shown that the 
resistance to CIA in the p19 knock-out mice correlated with an absence of IL-17-
producing CD4 T cells, while the induction of collagen-reactive Th1 cells was not 
affected. Hence, these data provided a link between IL-23 and the expansion of Th17 
cells in autoimmunity. Shortly after Oppmanns' study, Lubberts and van den Berg 
published that blocking of IL-17 suppressed CIA in DBA/1 mice231. Th17 driven 
autoimmunity has since been described for a number of experimental models, such as 
the K/B×N cell transfer model232 and the zymozan- or β-glucan-induced SKG model233.  
IL-23 is a key cytokine for a sustained Th17 response but it is not necessary for its 
induction. A number of independent studies in 2006 showed that two pleiotropic 
cytokines, IL-6 and TGF-", were essential for the induction of Th17 cells in mice234-236 
and humans237. In the absence of IL-6, polarization of Th17 cells is indeed defective and 
T cells instead succumb to a regulatory phenotype (manifested by the expression of the 
FoxP3 transcription factor). The inhibition of autoimmunity in mice deficient for IL-6 
appears to be dependent on the expansion of regulatory T cells, and upon depletion of 
FoxP3+ cells, IL-6 knock out mice regained their susceptibility. Moreover, another 
cytokine, IL-21, can induce Th17 differentiation in the absence of IL-6238.   
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Not all experimental arthritis models are mediated through Th17. The 
proteoglycan-induced arthritis model (PGIA) has been shown to be independent on IL-
17, and Th differentiation in most, if not all, of the rat adjuvant models are still poorly 
characterized. We have shown that IFN-# is important for the induction of arthritis in 
the PIA transfer model, while the role of Th17 cells in this model has still not been 
characterized201. However, we have now addressed the dependency of IFN-# and IL-17 
in the PIA model (Study II), and we are currently testing the requirement for IL-17 in 
the transfer model.  
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PRESENT INVESTIGATIONS 
 
 
STUDY I  
 
The major histocompatibility complex (MHC) is a major genetic determinant of thymic 
selection. However, studies in humans and mice have largely focused on the association 
to the classical MHC class I and II genes, while the influence of non-MHC genes is still 
unclear. In this study, we used an outbred cohort derived from 8 inbred rat strains to 
map variations in CD4 and CD8 T cell numbers and MHC class I and II expression. 
Blood from  ~1400 adult rats was analyzed by flow cytometry. Ten quantitative trait loci 
(QTLs) reached genome-wide significance (-logP < 4.3); 4 controlled CD4:CD8 ratio, 3 
surface expression of MHC class I and 3 surface expression of MHC class II. Three 
QTLs (one for each phenotype) were identified on chromosome 20 and spanned the 
MHC region. The confidence intervals of these QTLs were determined to 4.1-9.7 
megabases (Mb). To narrow down the QTL regions, we produced a panel of 
recombinant MHC-congenic strains (RCS). This panel was derived from four inbred 
MHC-congenic strains that shared a common genetic background (DA); DA.1I, 
DA.1F, DA.1H and DA.1U. We used a conventional intercross breeding to obtain 
crossovers in the MHC. Progenies were screened using 67 short-tandem repeat (STR) 
and SNP markers, which revealed a total of 70 recombinations. These recombinations 
were located within 5 distinct intervals, which largely overlapped with recombination 
hotspots in the human MHC (HLA-DM, BTNL2 and LTA). By congenic mapping, we 
could show that two minimal QTLs, a 0.282 Mb interval in the classical MHCIa region 
(T cell selection QTL 1, Tcs1) and a 0.206 Mb interval in the MHCII region (Tcs2), were 
responsible for the QTLs identified in the HS rats. Tcs1 was associated with variation in 
T cell numbers and MHC class I expression, whereas Tcs2 controlled T cell numbers, 
and both MHC class I and II expression. We showed further that these QTLs controlled 
the selection of T cells in the thymus rather than the expansion of CD4 and CD8 T cells 
in the periphery. Tcs2 contained 12 coding genes that were Sanger sequenced in the five 
parental strains to identify genetic variants associated with the mapped phenotypes. 
Polymorphisms in a gene encoding the ER transporter, Tap2, were found to be 
responsible for the variation in CD8 T cell numbers and MHC class I expression. We 
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conclude that surprisingly few regions in the genome (we found only one) control both 
MHC expression and T cells selection. The MHC region is an exception, in which two 
distinct sub-regions contribute to a significant overlap in phenotypes. These 
phenotypes are not solely regulated by classical MHC genes as the regulation by Tap2 
illustrates.  
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STUDY II 
 
In this study, we followed up Study I and analyzed the effect of Tcs1 and Tcs2 in 
pristane-induced arthritis (PIA). We show that Tcs2, a 206 kb chromosomal interval in 
the MHCII region, is associated with disease onset and severity at the acute stage of 
arthritis. However, neither incidence nor the severity of chronic arthritis was associated 
with MHCII. In contrast, genetic variation in the MHCI locus (Tcs1) did not affect the 
susceptibility to PIA. The arthritis was particularly severe in rats with RT1a (DA) and 
RT1f (DA.1FR9) haplotypes. These strains encode identical RT1-D genes (orthologues 
to HLA-DR), which suggested that RT1-D restricted T cells are important in PIA.  
However, antibodies that block RT1-D did not prevent arthritis when injected at the 
priming stage in PIA, while antibodies to RT1-B (HLA-DQ) did. The importance of 
RT1-B was further supported by the expression of this molecule on the cell surface of 
pristane primed APCs. While RT1-B was highly expressed on the cell surface of DCs, 
RT1-D instead accumulated intracellularly and was relatively weakly expressed on DCs. 
To identify which MHC class II-bound antigens are important for priming CD4 T cells 
in PIA, we analyzed the peptide ligandome of RT1-B and RT1-D molecules. We 
observed qualitative and quantitative differences in the peptide ligandome between the 
strains and between the MHC molecules. Peptides derived from ubiquitously expressed 
auto-antigens described in RA were identified; however, none of the identified peptides 
were specific to cartilage proteins, nor did they elicit a T cell response when added to 
pristane primed T cells ex-vivo. The Tcs2 interval regulates T cell selection as shown 
previously but neither frequency nor absolute numbers of CD4 and CD8 T cells 
correlated with arthritis susceptibility. However, the frequency of both CD4 and CD8 
recent thymic emigrants (RTEs) was greatest in rats that were protected from severe 
arthritis. Hence, we could show a correlation between thymic activity and arthritis 
susceptibility that was determined by MHCII. Surprisingly, T cells expanded more in 
arthritis-protected strains than in non-protected strains upon pristane injection, which 
correlated with the frequency of RTEs in these strains. Pristane-primed T cells in the 
least susceptible strain, DA.1HR61, contained less Th1 cells but more Th17 cells. This 
shift in Th subsets is likely to explain the arthritis protection in DA.1HR61 since 
neutralization of IFN-# suppressed disease when administrated during disease priming, 
while neutralization of IL-17 had no effect. However, the role of IFN-# and IL-17 was 
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the opposite in established disease: while neutralization of IFN-# was inefficient, 
neutralization of IL-17 was very effective in reducing inflammation, possibly by 
inhibiting recruitment of neutrophils to the joints. In conclusion, this study positions a 
206 kb region in the MHCII in an adjuvant model and shows that MHCII genes confer 
risk to acute but not chronic arthritis.  
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STUDY III 
 
Collagen type XI (CXI) is a heterotrimeric collagen and a minor constituent of cartilage. 
The alpha 3 polypeptide (!3) in CXI is encoded by COL2A1, which also codes for !1 of 
collagen type II (CII). Albeit identical amino acid sequences, !3(XI) and !1(II) differ in 
glycosylation pattern, which could influence T cell recognition. We show in this paper 
that MHC congenic DA.1F rats immunized with the non-antigenic mineral oil pristane 
develop T cell and antibody responses to CXI. The reactivity to CXI was confined to the 
chronic phase of the disease and specific for the RT1f haplotype. We separated the alpha 
constituents of CXI by HPLC and could show that the T cell response was specific for 
the !1 and !2 polypeptides, while no T cell response was detected for !3. Thus, post-
translational modifications of !3(XI) do not explain CXI immunity in pristane-induced 
arthritis. We further used DA.1F recombinant MHC congenic strains from Study I to 
map CXI immunity to an interval of approximately 0.2 Mb in the MHC-II region 
(Tcs2). Sequencing of the coding regions of the MHC class II genes (RT1-B and RT1-D) 
in DA.1F and DA showed that immunity to CXI is associated with RT1-B. Finally, we 
show that patients with early stage RA display increased serum reactivity to CXI, which 
is distinct from the response to CII.     
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STUDY IV 
 
This is the first paper describing the adoptive transfer of pristane-induced arthritis (PIA 
transfer). We show in this paper that T cells can be adoptively transferred from 
pristane-primed donor rats to naive recipient rats after re-stimulation in vitro with 
Concanavalin A (ConA) or different T cell receptor (TCR) V! and V" specific 
monoclonal antibodies. We determined the conditions necessary for T cells to become 
arthritogenic, which included dose of pristane, priming period and re-stimulation 
protocol. We show that PIA transfer is a mild disease compared to the induced model 
while the arthritis onset is earlier in the transfer model (day 5 in PIA transfer versus day 
10 in PIA). In addition, we show that the transfer model lacks the characteristic 
relapsing-remitting disease course typical for PIA and that the rats recover completely 
from arthritis 3-4 weeks post T cell transfer. We characterized the cellular compositions 
in synovia and blood of PIA rats and compared them to the blood of naive rats. This 
showed that highly activated T cells (CD54+, CD25+ and MHC-II+) in pristane primed 
rats migrated to the joints. When stimulated in vitro with ConA, these cells produced 
high levels of TNF-! and IFN-#, and anti-TNF-! (etanercept) and anti-IFN-# (DB-1) 
pre-treatment of recipient rats suppressed development of PIA transfer. We further 
determined MHC restriction in the model using MHC-congenic rats. We found that T 
cells transferred to allogenic, irradiated, recipients were unable to induce arthritis 
whereas T cells transferred to semi-allogenic or syngenic recipients induced arthritis. 
We finally showed that pre-treatment of recipient rats with anti-MHC-II monoclonal 
antibodies could suppress the disease induction, supporting that PIA is dependent on 
MHC class II restricted CD4+ T cells.         
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CONCLUDING REMARKS 
 
 
The work presented in this thesis aims to increase the understanding for the 
fundamental processes that concern antigen presentation, T cell selection and 
autoimmunity in the rat. Three of the included papers and manuscripts stem from the 
generation of a panel consisting of a large number of MHC recombinant inbred strains. 
Using a model that is essentially unique to the rat, we have shown that MHCII genes 
influence the onset, severity and progression of autoimmune disease, which has never 
been shown before. We could also show that T cells in the same model react upon 
challenge with the minor cartilage component collagen type XI and provided evidence 
for a similar function of this antigen in human RA. In addition, we showed a number of 
specific QTLs controlling CD4 and CD8 T cell numbers and provided evidence on gene 
level for an interaction between MHCI and MHCII genes. Finally, we described a new 
model for experimental arthritis in which the effector function of autoreactive T cells 
can be investigated.  
 
In summary, we have provided a physical set of minimal MHC fragments that positions 
a large number of immune related phenotypes of importance in humans. The panel of 
congenic strains that was established will remain as an important resource for further 
studies on the genetic variation in the MHC.  
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